Intensity Therapeutics In...

2.00
-0.06 (-2.91%)
At close: Apr 02, 2025, 3:59 PM
2.01
0.52%
After-hours: Apr 02, 2025, 07:55 PM EDT
-2.91%
Bid 1.95
Market Cap 30.31M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -1.17
PE Ratio (ttm) -1.71
Forward PE -1.95
Analyst Buy
Ask 2.07
Volume 22,008
Avg. Volume (20D) 34,606
Open 1.95
Previous Close 2.06
Day's Range 1.95 - 2.07
52-Week Range 1.50 - 5.28
Beta 4.59

About INTS

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & D...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2023
Employees 5
Stock Exchange NASDAQ
Ticker Symbol INTS
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for INTS stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 325.77% from the latest price.

Stock Forecasts
3 months ago
-12.34%
Intensity Therapeutics shares are trading lower. T... Unlock content with Pro Subscription